Advertisement

Journal of Computer-Aided Molecular Design

, Volume 32, Issue 12, pp 1347–1361 | Cite as

Quantum chemical and molecular mechanics studies on the assessment of interactions between resveratrol and mutant SOD1 (G93A) protein

  • E. Srinivasan
  • R. Rajasekaran
Article

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that has been associated with mutations in metalloenzyme superoxide dismutase (SOD1) causing protein structural destabilization and aggregation. However, the mechanistic action and the cure for the disease still remain obscure. Herein, we initially studied the conformational preferences of SOD1 protein structures upon substitution of Ala at Gly93 in comparison with that of wild type. Our results corroborated with the previous experimental studies on the aggregation and the destabilizing activity of mutant SOD1 protein G93A. On the therapeutic point of view, we computationally analyzed the influence of resveratrol, a natural polyphenol widely found in red wine on mutant SOD1 relative to wild type, using molecular docking studies. Further, FMO calculations were performed, using GAMESS to study the pair residual interaction on the wild type and mutant complex systems. Consequently, the resveratrol showed greater interaction with mutant than the wild type. Subsequently, we evaluated the conformational preferences of wild type and mutant complex systems, where the protein conformational structures of mutant that were earlier found to lose their conformational stability was regained, upon binding with resveratrol. Similar trend of results were found on the 2-D free energy landscapes of both the wild type and mutant systems. Hence, the combined biophysical and quantum chemical studies in our study supported the results of previous experimental studies, thereby stipulating an action of resveratrol on mutant SOD1 and paving a way for the design of highly potent effective inhibitors against fALS affecting the mankind.

Keywords

ALS SOD1 DMD Resveratrol Docking FMO 

Notes

Acknowledgements

The authors thank VIT University for providing ‘VIT SEED GRANT’ for carrying out this research work.

Compliance with ethical standards

Conflict of interest

The authors declare that there are no conflicts of interest.

Supplementary material

10822_2018_175_MOESM1_ESM.doc (66 kb)
Supplementary material 1 (DOC 66 KB)

References

  1. 1.
    Redler RL, Dokholyan NV (2012) The complex molecular biology of amyotrophic lateral sclerosis (ALS). Prog Mol Biol Transl Sci 107:215–262.  https://doi.org/10.1016/B978-0-12-385883-2.00002-3 CrossRefGoogle Scholar
  2. 2.
    Pratt AJ, Shin DS, Merz GE et al (2014) Aggregation propensities of superoxide dismutase G93 hotspot mutants mirror ALS clinical phenotypes. Proc Natl Acad Sci 111:E4568–E4576.  https://doi.org/10.1073/pnas.1308531111 CrossRefGoogle Scholar
  3. 3.
    Radunovic A, Leigh PN (1996) Cu/Zn superoxide dismutase gene mutations in amyotrophic lateral sclerosis: correlation between genotype and clinical features. J Neurol Neurosurg Psychiatry 61:565CrossRefGoogle Scholar
  4. 4.
    Julien J-P (2007) ALS: astrocytes move in as deadly neighbors. Nat Neurosci 10:535–537.  https://doi.org/10.1038/nn0507-535 CrossRefGoogle Scholar
  5. 5.
    Mulder DW, Kurland LT, Offord KP, Beard CM (1986) Familial adult motor neuron disease: amyotrophic lateral sclerosis. Neurology 36:511–517CrossRefGoogle Scholar
  6. 6.
    Kato S, Takikawa M, Nakashima K et al (2000) New consensus research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) gene mutations: inclusions containing SOD1 in neurons and astrocytes. Amyotroph Lateral Scler Mot Neuron Disord Off Publ World Fed Neurol Res Group Mot Neuron Dis 1:163–184CrossRefGoogle Scholar
  7. 7.
    Rakhit R, Chakrabartty A (2006) Structure, folding, and misfolding of Cu, Zn superoxide dismutase in amyotrophic lateral sclerosis. Biochim Biophys Acta BBA 1762:1025–1037.  https://doi.org/10.1016/j.bbadis.2006.05.004 CrossRefGoogle Scholar
  8. 8.
    Bruijn LI, Houseweart MK, Kato S et al (1998) Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281:1851–1854.  https://doi.org/10.1126/science.281.5384.1851 CrossRefGoogle Scholar
  9. 9.
    Schmidlin T, Ploeger K, Jonsson AL, Daggett V (2013) Early steps in thermal unfolding of superoxide dismutase 1 are similar to the conformational changes associated with the ALS-associated A4V mutation. Protein Eng Des Sel 26:503–513.  https://doi.org/10.1093/protein/gzt030 CrossRefGoogle Scholar
  10. 10.
    Qualls DA, Prudencio M, Roberts BL et al (2013) Features of wild-type human SOD1 limit interactions with misfolded aggregates of mouse G86R Sod1. Mol Neurodegener 8:46CrossRefGoogle Scholar
  11. 11.
    Das A, Plotkin SS (2013) Mechanical probes of SOD1 predict systematic trends in metal and dimer affinity of ALS-associated mutants. J Mol Biol 425:850–874.  https://doi.org/10.1016/j.jmb.2012.12.022 CrossRefGoogle Scholar
  12. 12.
    Srinivasan E, Rajasekaran R (2017) Exploring the cause of aggregation and reduced Zn binding affinity by G85R mutation in SOD1 rendering amyotrophic lateral sclerosis. Proteins Struct Funct Bioinform 85:1276–1286.  https://doi.org/10.1002/prot.25288 CrossRefGoogle Scholar
  13. 13.
    Srinivasan E, Rajasekaran R (2016) Computational simulation analysis on human SOD1 mutant (H80R) exposes the structural destabilization and the deviation of Zn binding that directs familial amyotrophic lateral sclerosis. J Biomol Struct Dyn.  https://doi.org/10.1080/07391102.2016.1227723 CrossRefGoogle Scholar
  14. 14.
    Srinivasan E, Sethumadhavan R, Rajasekaran R (2017) A theoretical study on Zn binding loop mutants instigating destabilization and metal binding loss in human SOD1 protein. J Mol Model 23:103.  https://doi.org/10.1007/s00894-017-3286-z CrossRefGoogle Scholar
  15. 15.
    Srinivasan E, Rajasekaran R (2018) Deciphering the loss of metal binding due to mutation D83G of human SOD1 protein causing FALS disease. Int J Biol Macromol 107:521–529.  https://doi.org/10.1016/j.ijbiomac.2017.09.019 CrossRefGoogle Scholar
  16. 16.
    Roberts BLT, Patel K, Brown HH, Borchelt DR (2012) Role of disulfide cross-linking of mutant SOD1 in the formation of inclusion-body-like structures. PLoS ONE 7:e47838.  https://doi.org/10.1371/journal.pone.0047838 CrossRefGoogle Scholar
  17. 17.
    Wu J, Shen E, Shi D et al (2012) Identification of a novel Cys146X mutation of SOD1 in familial amyotrophic lateral sclerosis by whole-exome sequencing. Genet Med 14:823–826.  https://doi.org/10.1038/gim.2012.50 CrossRefGoogle Scholar
  18. 18.
    Redler RL, Wilcox KC, Proctor EA et al (2011) Glutathionylation at Cys-111 induces dissociation of wild type and FALS mutant SOD1 dimers. Biochemistry 50:7057–7066.  https://doi.org/10.1021/bi200614y CrossRefGoogle Scholar
  19. 19.
    Fujiwara N, Nakano M, Kato S et al (2007) Oxidative modification to cysteine sulfonic acid of Cys111 in human copper-zinc superoxide dismutase. J Biol Chem 282:35933–35944.  https://doi.org/10.1074/jbc.M702941200 CrossRefGoogle Scholar
  20. 20.
    Srinivasan E, Rajasekaran R (2017) Cysteine to serine conversion at 111th position renders the disaggregation and retains the stabilization of detrimental SOD1 A4V mutant against amyotrophic lateral sclerosis in human—a discrete molecular dynamics study. Cell Biochem Biophys.  https://doi.org/10.1007/s12013-017-0830-5 CrossRefGoogle Scholar
  21. 21.
    Nagano S, Takahashi Y, Yamamoto K et al (2015) A cysteine residue affects the conformational state and neuronal toxicity of mutant SOD1 in mice: relevance to the pathogenesis of ALS. Hum Mol Genet 24:3427–3439.  https://doi.org/10.1093/hmg/ddv093 CrossRefGoogle Scholar
  22. 22.
    Achilli F, Boyle S, Kieran D et al (2005) The SOD1 transgene in the G93A mouse model of amyotrophic lateral sclerosis lies on distal mouse chromosome 12. Amyotroph Lateral Scler Mot Neuron Disord Off Publ World Fed Neurol Res Group Mot Neuron Dis 6:111–114.  https://doi.org/10.1080/14660820510035351 CrossRefGoogle Scholar
  23. 23.
    Matsumoto A, Okada Y, Nakamichi M et al (2006) Disease progression of human SOD1 (G93A) transgenic ALS model rats. J Neurosci Res 83:119–133.  https://doi.org/10.1002/jnr.20708 CrossRefGoogle Scholar
  24. 24.
    Museth AK, Brorsson A-C, Lundqvist M et al (2009) The ALS-associated mutation G93A in human copper-zinc superoxide dismutase selectively destabilizes the remote metal binding region. Biochemistry 48:8817–8829.  https://doi.org/10.1021/bi900703v CrossRefGoogle Scholar
  25. 25.
    Rocha MC, Pousinha PA, Correia AM et al (2013) Early changes of neuromuscular transmission in the SOD1(G93A) mice model of ALS start long before motor symptoms onset. PLoS ONE 8:e73846.  https://doi.org/10.1371/journal.pone.0073846 CrossRefGoogle Scholar
  26. 26.
    Shipp EL, Cantini F, Bertini I et al (2003) Dynamic properties of the G93A mutant of copper—zinc superoxide dismutase as detected by NMR spectroscopy: implications for the pathology of familial amyotrophic lateral sclerosis. Biochemistry 42:1890–1899.  https://doi.org/10.1021/bi026704y CrossRefGoogle Scholar
  27. 27.
    Banerjee V, Oren O, Ben-Zeev E et al (2017) A computational combinatorial approach identifies a protein inhibitor of superoxide dismutase 1 misfolding, aggregation, and cytotoxicity. J Biol Chem 292:15777–15788.  https://doi.org/10.1074/jbc.M117.789610 CrossRefGoogle Scholar
  28. 28.
    Auclair JR, Boggio KJ, Petsko GA et al (2010) Strategies for stabilizing superoxide dismutase (SOD1), the protein destabilized in the most common form of familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 107:21394–21399.  https://doi.org/10.1073/pnas.1015463107 CrossRefGoogle Scholar
  29. 29.
    Mancuso R, del Valle J, Modol L et al (2014) Resveratrol improves motoneuron function and extends survival in SOD1G93A ALS mice. Neurotherapeutics 11:419–432.  https://doi.org/10.1007/s13311-013-0253-y CrossRefGoogle Scholar
  30. 30.
    Porquet D, Griñán-Ferré C, Ferrer I et al (2014) Neuroprotective role of trans-resveratrol in a murine model of familial alzheimer’s disease. J Alzheimers Dis 42:1209–1220.  https://doi.org/10.3233/JAD-140444 CrossRefGoogle Scholar
  31. 31.
    Proctor EA, Dokholyan NV (2016) Applications of discrete molecular dynamics in biology and medicine. Curr Opin Struct Biol 37:9–13.  https://doi.org/10.1016/j.sbi.2015.11.001 CrossRefGoogle Scholar
  32. 32.
    Redler RL, Shirvanyants D, Dagliyan O et al (2014) Computational approaches to understanding protein aggregation in neurodegeneration. J Mol Cell Biol 6:104–115.  https://doi.org/10.1093/jmcb/mju007 CrossRefGoogle Scholar
  33. 33.
    Burns J, Yokota T, Ashihara H et al (2002) Plant foods and herbal sources of resveratrol. J Agric Food Chem 50:3337–3340CrossRefGoogle Scholar
  34. 34.
    Lekli I, Ray D, Das DK (2010) Longevity nutrients resveratrol, wines and grapes. Genes Nutr 5:55–60.  https://doi.org/10.1007/s12263-009-0145-2 CrossRefGoogle Scholar
  35. 35.
    Sun AY, Wang Q, Simonyi A, Sun GY (2010) Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol Neurobiol 41:375–383.  https://doi.org/10.1007/s12035-010-8111-y CrossRefGoogle Scholar
  36. 36.
    Tellone E, Galtieri A, Russo A et al (2015) Resveratrol: a focus on several neurodegenerative diseases. Oxid Med Cell Longev 2015:392169.  https://doi.org/10.1155/2015/392169 CrossRefGoogle Scholar
  37. 37.
    Vidavalur R, Otani H, Singal PK, Maulik N (2006) Significance of wine and resveratrol in cardiovascular disease: French paradox revisited. Exp Clin Cardiol 11:217–225Google Scholar
  38. 38.
    Potter KA, Buck AC, Self WK et al (2013) The effect of resveratrol on neurodegeneration and blood brain barrier stability surrounding intracortical microelectrodes. Biomaterials 34:7001–7015.  https://doi.org/10.1016/j.biomaterials.2013.05.035 CrossRefGoogle Scholar
  39. 39.
    Udenigwe CC, Ramprasath VR, Aluko RE, Jones PJH (2008) Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr Rev 66:445–454.  https://doi.org/10.1111/j.1753-4887.2008.00076.x CrossRefGoogle Scholar
  40. 40.
    Lu L, Zhu S, Zhang H et al (2015) Theoretical study of complexation of resveratrol with cyclodextrins and cucurbiturils: structure and antioxidative activity. RSC Adv 5:14114–14122.  https://doi.org/10.1039/C4RA14737E CrossRefGoogle Scholar
  41. 41.
    Villaflores OB, Chen Y-J, Chen C-P et al (2012) Curcuminoids and resveratrol as anti-Alzheimer agents. Taiwan J Obstet Gynecol 51:515–525.  https://doi.org/10.1016/j.tjog.2012.09.005 CrossRefGoogle Scholar
  42. 42.
    Cheng B, Gong H, Xiao H et al (2013) Inhibiting toxic aggregation of amyloidogenic proteins: atherapeutic strategy for protein misfolding diseases. Biochim Biophys Acta 1830:4860–4871.  https://doi.org/10.1016/j.bbagen.2013.06.029 CrossRefGoogle Scholar
  43. 43.
    Radovan D, Opitz N, Winter R (2009) Fluorescence microscopy studies on islet amyloid polypeptide fibrillation at heterogeneous and cellular membrane interfaces and its inhibition by resveratrol. FEBS Lett 583:1439–1445.  https://doi.org/10.1016/j.febslet.2009.03.059 CrossRefGoogle Scholar
  44. 44.
    Feng Y, Wang X, Yang S et al (2009) Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation. Neurotoxicology 30:986–995.  https://doi.org/10.1016/j.neuro.2009.08.013 CrossRefGoogle Scholar
  45. 45.
    Jiang P, Li W, Shea J-E, Mu Y (2011) Resveratrol inhibits the formation of multiple-layered β-sheet oligomers of the human islet amyloid polypeptide segment 22–27. Biophys J 100:1550–1558.  https://doi.org/10.1016/j.bpj.2011.02.010 CrossRefGoogle Scholar
  46. 46.
    Berman HM, Westbrook J, Feng Z et al (2000) The protein data bank. Nucleic Acids Res 28:235–242CrossRefGoogle Scholar
  47. 47.
    Hess B, Kutzner C, van der Spoel D, Lindahl E (2008) GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 4:435–447.  https://doi.org/10.1021/ct700301q CrossRefGoogle Scholar
  48. 48.
    Darden T, York D, Pedersen L (1993) Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems. J Chem Phys 98:10089.  https://doi.org/10.1063/1.464397 CrossRefGoogle Scholar
  49. 49.
    Kim S, Thiessen PA, Bolton EE et al (2016) PubChem substance and compound databases. Nucleic Acids Res 44:D1202–D1213.  https://doi.org/10.1093/nar/gkv951 CrossRefGoogle Scholar
  50. 50.
    Getov I, Petukh M, Alexov E (2016) SAAFEC: predicting the effect of single point mutations on protein folding free energy using a knowledge-modified MM/PBSA approach. Int J Mol Sci.  https://doi.org/10.3390/ijms17040512 CrossRefGoogle Scholar
  51. 51.
    Parthiban V, Gromiha MM, Schomburg D (2006) CUPSAT: prediction of protein stability upon point mutations. Nucleic Acids Res 34:W239–W242.  https://doi.org/10.1093/nar/gkl190 CrossRefGoogle Scholar
  52. 52.
    Binkowski TA, Naghibzadeh S, Liang J (2003) CASTp: computed atlas of surface topography of proteins. Nucleic Acids Res 31:3352–3355CrossRefGoogle Scholar
  53. 53.
    Morris GM, Huey R, Lindstrom W et al (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30:2785–2791.  https://doi.org/10.1002/jcc.21256 CrossRefGoogle Scholar
  54. 54.
    Fedorov DG, Kitaura K (2004) The importance of three-body terms in the fragment molecular orbital method. J Chem Phys 120:6832–6840.  https://doi.org/10.1063/1.1687334 CrossRefGoogle Scholar
  55. 55.
    Schmidt MW, Baldridge KK, Boatz JA et al (1993) General atomic and molecular electronic structure system. J Comput Chem 14:1347–1363.  https://doi.org/10.1002/jcc.540141112 CrossRefGoogle Scholar
  56. 56.
    Shirvanyants D, Ding F, Tsao D et al (2012) Discrete molecular dynamics: an efficient and versatile simulation method for fine protein characterization. J Phys Chem B 116:8375–8382.  https://doi.org/10.1021/jp2114576 CrossRefGoogle Scholar
  57. 57.
    Ding F, Tsao D, Nie H, Dokholyan NV (2008) Ab initio folding of proteins with all-atom discrete molecular dynamics. Structure 16:1010–1018.  https://doi.org/10.1016/j.str.2008.03.013 CrossRefGoogle Scholar
  58. 58.
    Likić VA, Gooley PR, Speed TP, Strehler EE (2005) A statistical approach to the interpretation of molecular dynamics simulations of calmodulin equilibrium dynamics. Protein Sci Publ Protein Soc 14:2955–2963.  https://doi.org/10.1110/ps.051681605 CrossRefGoogle Scholar
  59. 59.
    Li N, Ma Z, Li M et al (2014) Natural potential therapeutic agents of neurodegenerative diseases from the traditional herbal medicine Chinese dragon’s blood. J Ethnopharmacol 152:508–521.  https://doi.org/10.1016/j.jep.2014.01.032 CrossRefGoogle Scholar
  60. 60.
    Ross CA, Poirier MA (2004) Protein aggregation and neurodegenerative disease. Nat Med.  https://doi.org/10.1038/nm1066 CrossRefGoogle Scholar
  61. 61.
    Matsumoto G, Stojanovic A, Holmberg CI et al (2005) Structural properties and neuronal toxicity of amyotrophic lateral sclerosis-associated Cu/Zn superoxide dismutase 1 aggregates. J Cell Biol 171:75–85.  https://doi.org/10.1083/jcb.200504050 CrossRefGoogle Scholar
  62. 62.
    Ferreira N, Saraiva MJ, Almeida MR (2011) Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Lett 585:2424–2430.  https://doi.org/10.1016/j.febslet.2011.06.030 CrossRefGoogle Scholar
  63. 63.
    Singh D, Gupta M, Kesharwani R et al (2014) Molecular drug targets and therapies for Alzheimer’s disease. Transl Neurosci.  https://doi.org/10.2478/s13380-014-0222-x CrossRefGoogle Scholar
  64. 64.
    Van Vuong Q, Bednarikova Z, Antosova A et al (2015) Inhibition of insulin amyloid fibrillization by glyco-acridines: an in vitro and in silico study. Med Chem Commun 6:810–822.  https://doi.org/10.1039/C5MD00004A CrossRefGoogle Scholar
  65. 65.
    Wise-Scira O, Dunn A, Aloglu AK et al (2013) Structures of the E46K mutant-type α-synuclein protein and impact of E46K mutation on the structures of the wild-type α-synuclein protein. ACS Chem Neurosci 4:498–508.  https://doi.org/10.1021/cn3002027 CrossRefGoogle Scholar
  66. 66.
    Stefani M (2004) Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. Biochim Biophys Acta 1739:5–25.  https://doi.org/10.1016/j.bbadis.2004.08.004 CrossRefGoogle Scholar
  67. 67.
    Sangwan S, Zhao A, Adams KL et al (2017) Atomic structure of a toxic, oligomeric segment of SOD1 linked to amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci 114:8770–8775.  https://doi.org/10.1073/pnas.1705091114 CrossRefGoogle Scholar
  68. 68.
    Ivanova MI, Sievers SA, Guenther EL et al (2014) Aggregation-triggering segments of SOD1 fibril formation support a common pathway for familial and sporadic ALS. Proc Natl Acad Sci USA 111:197–201.  https://doi.org/10.1073/pnas.1320786110 CrossRefGoogle Scholar
  69. 69.
    Patil R, Das S, Stanley A et al (2010) Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing. PLoS ONE.  https://doi.org/10.1371/journal.pone.0012029 CrossRefGoogle Scholar
  70. 70.
    Dangoumau A, Marouillat S, Burlaud Gaillard J et al (2015) Inhibition of pathogenic mutant SOD1 aggregation in cultured motor neuronal cells by prevention of its SUMOylation on lysine 75. Neurodegener Dis 16:161–171.  https://doi.org/10.1159/000439254 CrossRefGoogle Scholar
  71. 71.
    Viet MH, Ngo ST, Lam NS, Li MS (2011) Inhibition of aggregation of amyloid peptides by beta-sheet breaker peptides and their binding affinity. J Phys Chem B 115:7433–7446.  https://doi.org/10.1021/jp1116728 CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Bioinformatics Lab, Department of Biotechnology, School of Bio Sciences and TechnologyVIT (Deemed to be University)VelloreIndia

Personalised recommendations